IPO
Immunicum AB today announced that Nasdaq Stockholm decided to halt trading in the Company’s share as a result of share price movements.
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
Gamida Cell Ltd. filed for a $69 million initial public offering for the Nasdaq exchange, according to a filing submitted last week to the U.S. Securities and Exchange Commission, Israel’s Calcalist first reported last week.
Gritstone Oncology, Inc. today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
Fusion Antibodies plc announces that it has been informed by Alan Mawson, a Non-Executive Director of the Company, that on 24 September 2018 he purchased 8,500 ordinary shares in the Company (“Ordinary Shares”) at a price of 67 pence per Ordinary Share via his personal pension scheme.
Karolinska Development’s portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm.
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
New York-based Y-mAbs Therapeutics will look at securing $96 million through an initial public offering to support development of its antibody-based therapeutic treatments for cancer.
Tesaro, Inc., an oncology-focused biopharmaceutical company, announced its participation in two upcoming investor conferences.
PRESS RELEASES